COT statement On Tryptophan And The Eosinophilia-Myalgia Syndrome

The COT was asked to assess the available data on the eosinophilia-myalgia syndrome and to consider the risks posed by the addition of isolated tryptophan to foods, including dietary supplements. In December 2005, the COT agreed that the statement should be amended to state that the mean therapeutic dose referred to in the conclusion was without adverse effect and so represented a NOAEL.